Product Description
Befovacimab, previously known as BAY 1093884, is an IgG2 fully human monoclonal antibody engineered to bind to both the Kunitz 1 (K1) and Kunitz 2 (K2) domains of the TFPI
Mechanisms of Action: TFP Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Subcutaneous, Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Bayer
Company Location:
Company Founding Year: 1863
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Hemophilia A
Phase 1: Hemophilia B|Hemophilia A
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03996486 |
NCT03996486 | P1 |
Withdrawn |
Hemophilia A|Hemophilia B |
2020-05-29 |
12% |
2025-08-27 |
Primary Endpoints|Treatments |
NCT03481946 |
NCT03481946 | P1 |
Completed |
Hemophilia B|Hemophilia A |
2018-10-17 |
12% |
2019-03-22 |
Study Completion Date|Treatments|Trial Status |
NCT02571569 |
NCT02571569 | P1 |
Completed |
Hemophilia A|Hemophilia B |
2018-07-09 |
17% |
2019-03-20 |
Treatments |
JapicCTI-173617 |
JapicCTI-173617 | P1 |
Unknown |
Hemophilia A |
2017-07-01 |
|||
JapicCTI-184051 |
JapicCTI-184051 | P2 |
Unknown |
Hemophilia A |
2020-05-01 |
|||
NCT03597022 |
NCT03597022 | P2 |
Terminated |
Hemophilia A |
2019-10-15 |
15% |
2020-12-02 |
Primary Endpoints|Treatments |
2017-003324-67 |
n.a. | P2 |
Terminated |
Hemophilia A |
2019-10-15 |
15% |
2022-03-13 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|